-+ 0.00%
-+ 0.00%
-+ 0.00%
HLS Therapeutics Q3 2026 adjusted EBITDA rises year over year to USD 5 million
Share
Listen to the news
HLS Therapeutics Q3 2026 adjusted EBITDA rises year over year to USD 5 million
  • HLS Therapeutics’ third-quarter 2026 adjusted EBITDA rose to USD 5 million from a year earlier.
  • NILEMDO private insurance coverage reached more than 80% of privately insured Canadians; public listings are expected in H1 2027.
  • VERQUVO commercialization begins in Q1 2027 under a Bayer partnership, expanding the cardiovascular portfolio into heart failure.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HLS Therapeutics Inc. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending